Blueprint Medicines Corp Stock
Blueprint Medicines Corp Stock
Pros and Cons of Blueprint Medicines Corp in the next few years
Pros
Cons
Performance of Blueprint Medicines Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | - | - | - | - | - | - | - |
| Ironwood Pharmaceuticals | -1.040% | -4.592% | 37.500% | 7.471% | 40.602% | -63.844% | -57.011% |
| Novocure Ltd | -5.380% | -5.369% | 1.231% | -56.055% | -2.029% | -86.379% | -92.204% |
| Iovance Biotherapeutics Inc. | -1.250% | 3.626% | -1.301% | -64.063% | -12.036% | -64.125% | -94.835% |
News
Why Ford's Deal With Amazon Is Bigger Than You Think
Ford Motor Company (NYSE: F) has made a groundbreaking move in automotive retail, announcing a partnership to sell its certified pre-owned (CPO) vehicles directly on Amazon (NASDAQ: AMZN).
This
Time to Take Notice: PEGA’s GenAI Blueprint Delivers Huge Q3 Beat
On a day that saw a handful of highly impressive earnings reports, tech stock Pegasystems (NASDAQ: PEGA) more than held its own. Shares blasted up by 15% on Oct. 22 as the market digested the
PEGA Surges 14%: There's Still Time to Ride This GenAI Innovator
For the second quarter in a row, artificial intelligence (AI) tech stock Pegasystems (NASDAQ: PEGA) crushed expectations.
Shares soared 14% on July 22 as the company eclipsed Wall Street

